SEC Form D private-offering filing

ABLi Therapeutics, Inc.

Name: ABLi Therapeutics, Inc. - new SEC Form D private-offering filing, Atlanta, GA
Published: 2026-01-13

A new SEC Form D private-offering notice from Atlanta, GA, a $1,000,000 filer-stated offering target in Biotech. The source filing is one click away.

ABLi Therapeutics, Inc. site↗ Verified via SEC Form D

Develops small molecule c-Abl kinase inhibitor therapies, led by risvodetinib, for Parkinson's disease and other neurodegenerative disorders.

Filed 2026-01-13Filed to raise $1,000,000First money in 2025-09-15Raised so far $1,000,000HQ (as filed) Atlanta, GASector Biotech ✓Stage (inferred) SeedCall status Late filing

Source linked the Form D on EDGAR↗Website verified ablitherapeutics.com↗Named in the filing 4 executives & directors

Open this row on the live feed →More new filings in Georgia →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.